Inclusion Criteria

The patient must fall into one of the following diagnostic categories:

Ewing's sarcoma family of tumors (ESF): Includes Ewing's sarcoma (classic, atypical,
extra-osseous), primitive sarcoma of bone, ectomesenchymoma, or peripheral primitive
neuroectodermal tumor (peripheral neuroepithelioma).

Rhabdomyosarcoma: The patient must have either

High-risk arm: Metastatic disease at diagnosis (any site, any histology);

OR

Moderate-risk arm: Incompletely resected ( Clinical Group III) Stage II tumors and ALL
stage III tumors (regardless of degree of surgical resection).

Neuroblastoma: Any patient with metastatic disease at diagnosis (POG stage D or Evans'
stage IV); or, patients with loco-regional metastatic disease (POG stage C) or tumor
infiltrating across the midline (Evans' stage III) IF they have an elevated serum ferritin
(greater than 142 ng/ml), an amplified N-myc copy number (greater than 10 copies on
Southern analysis), or a DNA index of greater than 1.1.

The patient must not have been previously treated with chemotherapy or radiation therapy.

Patients must be greater than or equal to 1 year of age but less than or equal to 25 years
of age. Patients weight must be greater than or equal to 15 kg.

The patient (or his/her guardian if less than 18 years of age) must sign a document
indicating that he/she is aware of the investigational nature of this treatment protocol
and the potential risks and benefits that may be expected.

Potentially fertile female patients must have a documented negative urine or serum
pregnancy test.

Patients must have a documented negative HIV serologic evaluation (Western Blot and/or
ELISA).

Patients must not have abnormal cardiac function (left ventricular ejection fraction less
than 45% as measured by gated equilibrium radionuclide angiography [MUGA scan] and
confirmed by echocardiography).

Patients must not have impaired renal function (serum creatinine greater than or equal to
twice the upper limit of normal for age).

Patients with a total bilirubin of greater than 4.0 mg/dl (or a direct bilirubin of
greater than 2.0 mg/dl) or SGOT/SGPT greater than five times the upper limits of normal
(NOT on the basis of hepatic involvement by tumor) will be excluded.

Patients with a second malignancy following previous therapy will be excluded.

Patients previously treated with chemotherapy or radiation therapy (other than limited,
emergency radiation therapy) will be excluded.

Patients who are HIV-infected will be excluced.